Evidence map›Paper›PMID 41999487›Full record

ArticleAnnals of hematology2026

Age and gender effects on molecular responses in chronic myeloid leukemia patients by first-line treatment: an Italian CML network cohort study.

Massimo Breccia, Valentina Giai, Tiziana Rosso, Patrizia Pregno, Fausto Castagnetti, Massimiliano Bonifacio, Isabella Capodanno, Mario Tiribelli, Fabio Stagno, Giovanni Caocci and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Massimo BrecciaHematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Via Benevento 6, Rome, 00161, Italy. breccia@bce.uniroma1.it.
Valentina GiaiDivision of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
Tiziana RossoCancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Torino, Italy.
Patrizia PregnoDivision of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
Fausto CastagnettiDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Institute of Hematology "L. & A. Seràgnoli", Bologna, Italy.
Massimiliano BonifacioDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Isabella CapodannoHematology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Mario TiribelliDivision of Hematology and BMT, Azienda Ospedaliero-Universitaria di Udine, Udine, Italy.
Fabio StagnoHematology Section AOU Policlinico " G.Martino", University of Messina, Messina, Italy.
Giovanni CaocciDepartment of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Antonella GozziniHematology, University of Florence, Florence, Italy.
Andrea PatriarcaDepartment of Translational Medicine, Universita degli Studi del Piemonte Orientale Amedeo Avogadro, Novara, Italy.
Federica SoràHematology and Transplant, University Cattolica del Sacro Cuore, Roma, Italy.
Giuseppina LoglisciHematology, Vito Fazzi Hospital, Lecce, Italy.
Antonella Russo RossiHematology, University of Bari, Bari, Italy.
Maria Rosaria CoppiHematology, Antonio Perrino Hospital, Brindisi, Italy.
Maria Cristina MiggianoOspedale S. Bortolo, Vicenza, Italy.
Francesco Di RaimondoPoliclinico - Vittorio Emanuele P.O. G. Rodolico, Università CATANIA, Catania, Italy.
Sara GalimbertiDipt Ematologia, Università di Pisa, Pisa, Italy.
Gianantonio RostiIRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori", Scientific Directorate, Meldola, Italy.
Lorella MelilloHematology, Policlinico Foggia, Foggia, Italy.
Fabrizio PaneCEINGE Biotecnologie Avanzate and Department of Biochemistry and Medical Biotechnology, University of Napoli Federico II, Napoli, Italy.
Giuseppe SaglioDepartment of Clinical and Biological Sciences, University of Turin, Torino, Italy.
Giovannino CicconeClinical Epidemiology Unit, AOU Città della Salute e della Scienza di Torino and Department of Medical Sciences, University of Turin, Torino, Italy.
Giorgina SpecchiaHematology, University of Bari, Bari, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among prognostic factors influencing the achievement of molecular responses in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs), age has been suggested with contrasting results, while the role of gender is still uncertain. A large cohort of 1,394 newly diagnosed CML patients was analyzed by data collected in the Italian CML Network, evaluating the effect of age and gender on the probability of deep molecular responses (DMR). With a median follow-up of 5 years, female patients showed a higher rate of DMR as compared to males. The effect, constant over time, was more evident with imatinib and dasatinib. Indeed, age did not influence the probability of DMR, when considered overall or stratified according to the type of TKI. In a real-world analysis, it seems that age has no effect on DMR regardless of the TKI class, while female gender can be confirmed as significant prognostic factor.

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsAdolescentAdultAgedAged, 80 and overAge FactorsAntineoplastic AgentsCohort StudiesDasatinibFemaleFollow-Up StudiesHumansImatinib MesylateItalyMaleAntineoplastic AgentsDasatinibImatinib MesylateProtein Kinase Inhibitors

Identifiers

PMID41999487
PMCPMC13091863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.